DDInter108 DDInter782
Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases[Label,A6897]. It is marketed under the name Eliquis[Label,L6043]. Apixaban was approved by the FDA on December 28, 2012.
In April 2018, the U.S. Food and Drug Administration (FDA) and the Swiss company Helsinn approved the intravenous formulation of AKYNZEO® (NEPA, a fixed antiemetic combination of fosnetupitant, 235mg, and palonosetron, 0.25mg) as an alternative treatment option for patients experiencing chemotherapy-induced nausea and vomiting . Fosnetupitant is the pro-drug form of netupitant [FDA label]. Generally, 25% to 30% of patients with a diagnosis of cancer receive chemotherapy as a treatment modality and 70% to 80% of these patients undergoing chemotherapy treatment may experience nausea and vomiting as major side effects. Considered one of the most distressing side effects of chemotherapy, nausea and vomiting has an immense impact on the quality of life of patients receiving certain antineoplastic therapies .
Apixaban {u} (Compound) binds {v} (Gene) CYP2C8
Apixaban {u} (Compound) causes {v} (Side Effect) Incision site haemorrhage
Apixaban {u} may cause a minor interaction that can limit clinical effects when taken with {v} Capsicum
Apixaban {u} may cause a minor interaction that can limit clinical effects when taken with {v} Modafinil
Apixaban {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Duloxetine
Apixaban {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Eliglustat
Apixaban {u} may lead to a major life threatening interaction when taken with {v} Desirudin
Apixaban {u} may lead to a major life threatening interaction when taken with {v} Trastuzumab emtansine
Apixaban (Compound) binds CYP2C8 (Gene)
Apixaban (Compound) causes Incision site haemorrhage (Side Effect)
Apixaban may cause a minor interaction that can limit clinical effects when taken with Capsicum
Apixaban may cause a minor interaction that can limit clinical effects when taken with Modafinil
Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Duloxetine
Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat
Apixaban may lead to a major life threatening interaction when taken with Desirudin
Apixaban may lead to a major life threatening interaction when taken with Trastuzumab emtansine